Type 1 diabetes and glucose monitoring

Diabetes Care

Volumn 30, Issue 11, 2007, Pages 2965-2971

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; INSULIN; INTERLEUKIN 4; INTERLEUKIN 5; LOW DENSITY LIPOPROTEIN; SOMATOSTATIN; TRIACYLGLYCEROL;

AUTOIMMUNITY; B LYMPHOCYTE; BODY MASS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEATH; DISEASE DURATION; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MONITORING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS BIOPSY; PHYSICIAN; TH2 CELL;

EID: 36049028684     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-zb11     Document Type: Conference Paper

References (24)

1. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC: Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48:2221-2228, 2005
2. Hillman M, Torn C, Thorgeirsson H, Landin-Olsson M: IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes. Diabetologia 47:1984-1999, 2004
3. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial. Ann Intern Med 128:517-523, 1998
4. Kuroda A, Yamasaki Y, Imagawa A: Betacell regeneration in a patient with type 1 diabetes mellitus who was receiving immunosuppressive therapy (Letter). Ann Intern Med 139:W81, 2003
5. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687, 2006
6. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E: Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25:1439-1443, 2002
7. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
8. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
9. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30:263-269, 2007
10. 1c in the Diabetes Control and Complications Trial. Diabetes Care 25:275-278, 2002
11. Kilpatrick ES, Rigby AS, Atkin SL: Variability in the relationship between mean plasma glucose and HbA1C: implications for the assessment of glycemic control. Clin Chem 53:897-901, 2007
12. Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486-1490, 2006
13. Service FJ, O'Brien PC: The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 44:1215-1220, 2001
14. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
15. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L: Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 29:44-50, 2006
16. 1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 29:2644-2649, 2006
17. Wilson DM, Beck RW, Tamborlane WV, Dontchev MJ, Kollman C, Chase P, Fox LA, Ruedy KJ, Tsalikian E, Weinzimer SA; DirecNet Study Group: The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with type 1 diabetes. Diabetes Care 30:59-64, 2007
18. Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV: Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 30:1125-1130, 2007
19. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P: A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 24:2030-2034, 2001
20. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 29:2730-2732, 2006
21. Halvorson M, Carpenter S, Kaiserman K, Kaufman FR: A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump. J Pediatr 150:103-105, 2007
22. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF: Insulin omission in women with IDDM. Diabetes Care 17:1178-1185, 1994
23. Choleau C, Dokladal P, Klein JC, Ward WK, Wilson GS, Reach G: Prevention of hypoglycemia using risk assessment with a continuous glucose monitoring system. Diabetes 51:3263-3273, 2002
24. Fiallo-Scharer R; Diabetes Research in Children Network Study Group: Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. J Clin Endocrinol Metab 90:3387-3391, 2005